San Diego, CA, United States
San Diego, CA, United States

Time filter

Source Type

Patent
Alcon and Kalypsys Inc. | Date: 2011-11-21

The present invention relates to compounds and methods which may be useful as inhibitors of H_(1)R and/or H_(4)R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.


Bischoff E.D.,Kalypsys Inc. | Bischoff E.D.,Exelixis | Daige C.L.,Kalypsys Inc. | Daige C.L.,Exelixis | And 6 more authors.
Journal of Lipid Research | Year: 2010

The liver X receptors LXRα and LXRβ play critical roles in maintaining lipid homeostasis by functioning as transcription factors that regulate genetic networks controlling the transport, catabolism, and excretion of cholesterol. The studies described in this report examine the individual anti-atherogenic activity of LXRα and LXRβ and determine the ability of each subtype to mediate the biological response to LXR agonists. Utilizing individual knockouts of LXRα and LXRβ in the Ldlr-/- background, we demonstrate that LXRα has a dominant role in limiting atherosclerosis in vivo. Functional studies in macrophages indicate that LXRα is required for a robust response to LXR ligands, whereas LXRβ functions more strongly as a repressor. Furthermore, selective knockout of LXRα in hematopoietic cells and rescue experiments indicate that the anti-atherogenic activity of this LXR subtype is not restricted to macrophages. These studies indicate that LXRα plays a selective role in limiting atherosclerosis in response to hyperlipidemia. Copyright © 2010 by the American Society for Biochemistry and Molecular Biology, Inc.


Patent
Kalypsys Inc. | Date: 2012-06-28

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.


The present invention relates to compounds and methods which may be useful as inhibitors of H_(1)R and/or H_(4)R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.


The present invention relates to compounds and methods which may be useful as inhibitors of H_(4)R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.


The present invention relates to compounds and methods which may be useful as inhibitors of H_(1)R and/or H_(4)R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.


Patent
Kalypsys Inc. | Date: 2012-02-10

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.


Disclosed herein are new methods of treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver in a subject by modulating PPAR with sulfonyl-substituted bicyclic compounds and compositions as pharmaceuticals.


Patent
Kalypsys Inc. | Date: 2011-11-07

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.


The present invention relates to salts, hydrates, and polymorphs of bicyclic heteroaryl compounds, and pharmaceutical compositions thereof, which may be useful as inhibitors of H_(4)R for the treatment or prevention of diseases including allergic rhinitis.

Loading Kalypsys Inc. collaborators
Loading Kalypsys Inc. collaborators